Overactive Bladder
Overactive Bladder is a renal health condition involving urinary symptoms such as urinary urgency and nocturia, meaning nighttime urination. These symptoms describe the condition itself, rather than a treatment.
See where Overactive Bladder fits within the renal health category and explore this topic in context.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Red Light Therapy (Photobiomodulation)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
In an RCT, 160 participants had reductions in UUI and incontinence episodes compared with sham. The finding relates to these outcomes; it does not establish effects on other bladder symptoms.
Open the Red Light Therapy (Photobiomodulation) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesRed Light Therapy (Photobiomodulation)CertaintyLowSourceRCT
In an RCT, 160 participants had reductions in UUI and incontinence episodes compared with sham. The finding relates to these outcomes; it does not establish effects on other bladder symptoms.
Who was studied
- People with a condition
Open Red Light Therapy (Photobiomodulation)Study result
RCT showing significant reduction in UUI and incontinence episodes compared with sham.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Overactive Bladder worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Overactive Bladder is a renal health condition involving urinary symptoms such as urinary urgency and nocturia, meaning nighttime urination. These symptoms describe the condition itself, rather than a treatment. Glycine has been studied in relation to overactive bladder symptoms, including urinary urgency and nocturia.
Evidence-backed options
Glycine is associated with a low level of evidence for overactive bladder. The reported use was oral glycine at 3 g X 2/day over 4 weeks. During that period, sleep latency decreased, and positive effects were reported for prostate symptoms, including nocturia and urinary urgency.
The reported time frame is 4 weeks; no more specific onset of effects is provided. The finding connects glycine with changes in sleep latency and urinary symptoms, but it does not establish how quickly either change may appear or whether the effects extend to other overactive bladder symptoms. The health status of the people studied was not specified, which limits how confidently the findings can be applied to particular groups.
This option is supported by a review, but the overall evidence is rated low, so the findings should be interpreted cautiously. For a medical condition such as overactive bladder, discussion with a clinician can help place this information in the context of symptoms and other care.